IRUS Total

A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China

File Description SizeFormat 
HCheng et al manuscript_reversion.docAccepted version246.5 kBMicrosoft WordView/Open
Title: A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China
Authors: Cheng, H
Yan, D
Zuo, X
Liu, J
Liu, W
Zhang, Y
Item Type: Journal Article
Abstract: Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy but it has severe side-effects. HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. In this retrospective report, we had genotyped HLA-B*5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications. We found 30 carriers of HLA-B*5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B*5801 positive and negative groups. The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated the HLA-B*5801 screening had significant cost benefit for clinical management. HLA-B*5801 allele should be screened in all patients with hyperuiciemia and gout in the Chinese population.
Issue Date: 1-May-2018
Date of Acceptance: 13-Mar-2018
URI: http://hdl.handle.net/10044/1/58036
DOI: https://dx.doi.org/10.1097/FPC.0000000000000334
ISSN: 1744-6872
Publisher: Lippincott, Williams & Wilkins
Start Page: 117
End Page: 124
Journal / Book Title: Pharmacogenetics and Genomics
Volume: 28
Issue: 5
Copyright Statement: © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: 0604 Genetics
1115 Pharmacology And Pharmaceutical Sciences
Pharmacology & Pharmacy
Publication Status: Published
Appears in Collections:National Heart and Lung Institute